STOCK TITAN
  1. Home
  2. Sec-filings
  3. AIM
  4. [EFFECT] AIM ImmunoTech Inc. SEC Filing

[EFFECT] AIM ImmunoTech Inc. SEC Filing

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
EFFECT
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Notice of Effectiveness
Effectiveness Date: July 3, 2025 4:00 P.M.
Form: S-3
CIK: 0000946644
Company Name: AIM ImmunoTech Inc.
File Number: 333-286319

Source: View Original Filing on SEC EDGAR

Aim Immunotech

NYSE:AIM

View AIM Stock Overview →

AIM Rankings

#6802 Ranked by Market Cap
N/A Ranked by Dividends
#52 Top Loser

AIM Latest News

Mar 18, 2026
AIM ImmunoTech Announces Final Approval of Novel Cancer Therapy Patent in Japan Combining Ampligen with Checkpoint Inhibitors
Mar 6, 2026
AIM ImmunoTech Announces Closing of its Rights Offering
Mar 4, 2026
AIM ImmunoTech Announces Expiration and Preliminary Results of its Rights Offering for Aggregate Gross Proceeds of $1.8 Million
Mar 2, 2026
AIM ImmunoTech Signs Agreement for Planning of a Proposed Phase 3 Clinical Trial of Ampligen in the Treatment of Late-Stage Pancreatic Cancer
Feb 27, 2026
AIM ImmunoTech Reminds Stockholders of March 3, 2026 Expiration Date and Updates Terms of Previously Announced Rights Offering

AIM Latest SEC Filings

Mar 16, 2026
[Form 4] AIM ImmunoTech Inc. Insider Trading Activity
Mar 16, 2026
[Form 4] AIM ImmunoTech Inc. Insider Trading Activity
Mar 10, 2026
[Form 4] AIM ImmunoTech Inc. Insider Trading Activity
Mar 10, 2026
[Form 4] AIM ImmunoTech Inc. Insider Trading Activity
Mar 6, 2026
[8-K] AIM ImmunoTech Inc. Reports Material Event

AIM Stock Data

4.03M
3.87M
Biotechnology
Biological Products, (no Diagnostic Substances)
Link
United States
OCALA